Philip J. Gold, M.D.

Philip J. Gold, M.D.

Medical Oncologist

Medical Oncology

4.7 out of 5.0
Rating 4.7
(76 Reviews)
Accepting New Patients
Medical Oncology - Swedish Cancer Institute First Hill
1221 Madison Street
Suite 200
Seattle, WA 98104
US
Phone
Main Number

About Philip J. Gold, M.D.

Philip J. Gold, MD, is Director of Clinical Research and the Program Leader for the Gastrointestinal (GI) Oncology Program at the Swedish Cancer Institute in Seattle, Washington. In 1991, Dr. Gold obtained his degree in medicine with a distinction in research at the University of Miami School of Medicine in Florida. He then completed an internal medicine internship and residency at the University of Washington. Dr. Gold received the Amgen Oncology Fellowship Award while he was training in medical oncology at the University of Washington School of Medicine and the Fred Hutchinson Cancer Research Center. Presently, he is board certified in medical oncology. Dr. Gold's clinical investigations on GI tumors, and particularly colorectal cancer treatment, can be found in peer-reviewed publications like the Journal of Clinical Oncology, Seminars in Oncology, and Cancer Investigation. Furthermore, he currently serves as a member of the NCI Colon Task Force, and the Southwest Oncology Group, where he serves as the subcommittee co-chair for colon cancer. In his free time, Dr. Gold enjoys photography and spending time with his wife and three sons.

Education

  • University of Washington, WA - Medical Oncology; Fred Hutchinson Cancer Research Center, WA
    Fellowship
  • University of Washington School of Medicine
    Residency
  • University of Miami Leonard M. Miller School of Medicine
    Medical School

Board Certifications

  • American Board of Internal Medicine - Medical Oncology

Publications

Languages

Insurances Accepted

  • Aetna Medicare Advantage HMO
  • Aetna Medicare Advantage PPO
  • Aetna PPO
  • Amerigroup - Medicare Advantage
  • Cigna PPO
  • Community Health Plan of Washington (WA Apple Health)
  • Coordinated care (WA Apple Health)
  • First Health/Coventry PPO
  • Health Net - TriCare
  • Humana - ChoiceCare PPO
  • Humana Medicare Advantage HMO
  • International Community Health Services Pace Program
  • Kaiser Foundation
  • Medicare
  • Molina
  • Molina Healthcare (WA Apple Health/Healthy Options)
  • Multiplan PPO
  • Premera Medicare Advantage HMO
  • Providence Health Plan
  • Providence Health Plan - Medicaid
  • Providence Health Plan - Medicare Advantage
  • Regence BlueShield of Washington
  • United Healthcare HMO
  • United Healthcare Medicare Advantage
  • United HealthCare PPO
  • WellCare

Clinical Interests

  • anal cancer
  • anorectal cancer
  • appendiceal cancer
  • biliary tract cancer
  • cancer
  • cancer chemotherapy
  • cancer during pregnancy
  • cancer genomics
  • cancer survivor
  • carcinoid of stomach
  • carcinoid tumor
  • carcinoid tumor of pancreas
  • cholangiocarcinoma
  • colon cancer
  • colon cancer chemotherapy
  • colorectal cancer
  • cystadenoma of pancreas
  • egfr mutation
  • endocrine complications of cancer therapy
  • gallbladder cancer
  • gastrin secreting tumor of pancreas
  • gastroesophageal junction cancer
  • gastrointestinal (gi) cancer
  • gastrointestinal (gi) cancer genomics
  • gastrointestinal stromal tumors (gist)
  • hepatoblastoma
  • insulinoma
  • islet cell tumor
  • liver mass
  • lynch syndrome
  • malignant neoplasm of liver
  • malignant neoplasm of pancreatic duct
  • malignant rectal neoplasm
  • malignant tumor of extrahepatic bile duct
  • metastatic colon cancer
  • metastatic liver cancer
  • neuroendocrine tumors
  • pancreas cancer
  • pancreas head cancer
  • pancreas tail cancer
  • pancreatic mass
  • personal history of malignant neoplasm of liver
  • plasma cell dyscrasia
  • pseudomyxoma peritonei
  • pulmonary metastases
  • recurrent colorectal cancer
  • small bowel cancer
  • stomach cancer
  • teratogen exposure
  • unknown primary cancer

Other Locations

Patient Reviews
4.7 out of 5.0(76 Reviews)

The Patient Rating score is based on responses given during the CAHPS Patient Experience Survey. Comments are also gathered from the same survey and displayed in their entirety with the exception of any language that may be considered slander, libel or contain private health information, which will be removed prior to publishing the comments. Responses are measured on a 10 - point scale, with 10 being the best score. These scores are then translated to a 5 - point scale in order to display results in a 5 - star rating.